This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
Eli Lilly raises 2026 outlook again as Q2 soars past estimates
Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.
By Pharmaceutical Technology
· Aug 6, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. …
The WeekFierceBiotech ↗
A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to foc…
The WeekBriefing
Takeda won FDA approval for Orzeyful in adults with narcolepsy type 1. The decision introduces the first appro…